More than 10 million people fall sick with tuberculosis (TB) every year. The disease remains the world’s biggest infectious disease killers with an estimated 1.25 million annual deaths. The disease is ...

A new national cohort study provides important insights into the treatment of multidrug-resistant tuberculosis (MDR-TB). The study shows that long-term disease-free survival rates are significantly ...

Multidrug-resistant tuberculosis (MDR-TB) poses a formidable challenge to global health, defined by resistance to at least isoniazid and rifampicin. Traditional treatment regimens are lengthy, toxic ...

A modified compound taken from bloodroot, a wildflower native to North America, effectively fights multidrug-resistant tuberculosis (TB) bacteria in the test tube, according to a new study. The ...

An international research team headed by scientists at the University of British Columbia has demonstrated how a novel semi-synthetic compound derived from sanguinarine (SG), an alkaloid extracted ...

A new study identified that a semi-synthetic compound can be derived from natural compounds and shows potent activity against tuberculosis (TB), including multi-drug resistant TB. A new study ...

A new study uncovers vulnerabilities in drug-resistant TB, offering hope for improved treatments. Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works ...

Despite global efforts, multidrug-resistant tuberculosis in children is rising at an alarming rate, with younger children at the highest risk of mortality—urgent action is needed to reverse the trend.

The discovery of a new preclinical compound with strong antifungal activity against multidrug-resistant pathogens is described in Nature. The drug, named mandimycin, is a member of a known family of ...